Alcobra’s ADHD drug fails late-stage study
(Reuters) – Israeli drug developer Alcobra Ltd on Tuesday said its experimental drug to treat attention deficit hyperactivity disorder (ADHD) failed a late-stage study in adult patients.
Alcobra will take a decision on the drug, MDX, after reviewing the full data set, Chief Executive Dr. Yaron Daniely said.
MDX, Alcobra’s only drug, has already hit a few roadblocks. The announcement follows the recommendation of the U.S. Food and Drug Administration this month that the company conduct a new MDX trial to expel safety concerns emanating from preclinical data.
The FDA had placed a clinical hold on the long-acting therapy in September in light of this data.
(Reporting by Natalie Grover in Bengaluru; Editing by Martina D’Couto)